These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24438770)

  • 21. WHO recommendations for misoprostol use for obstetric and gynecologic indications.
    Tang J; Kapp N; Dragoman M; de Souza JP
    Int J Gynaecol Obstet; 2013 May; 121(2):186-9. PubMed ID: 23433680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of misoprostol in obstetrics].
    Capilla Montes C; Bermejo Vicedo T
    Farm Hosp; 2005; 29(3):177-84. PubMed ID: 16013944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-label use of misoprostol for labor induction: a nation-wide survey in Switzerland.
    Krause E; Malorgio S; Kuhn A; Schmid C; Baumann M; Surbek D
    Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):324-8. PubMed ID: 21958953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Off-label drug use of the misoprostol in gynecology & obstetrics: From a medico-economics benefit to a potential legal risk].
    Decamps-Mini D; Pelofi J; Treisser A
    Gynecol Obstet Fertil; 2015 Jun; 43(6):453-8. PubMed ID: 26032707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Misoprostol for postpartum haemorrhage.
    Drug Ther Bull; 2010 Jun; 48(6):66-9. PubMed ID: 20530028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of intravenous oxytocin to vaginal misoprostol for mid trimester labor induction.
    Hidar S; Jerbi M; Khaïri H
    Am J Obstet Gynecol; 2006 Jul; 195(1):332-3; author reply 333-4. PubMed ID: 16813766
    [No Abstract]   [Full Text] [Related]  

  • 27. [Conflicting recommendations between the French national authority for health (HAS) and clinical practice guidelines (CNGOF); focus on 200 late medical abortions, conducted outside marketing authorizations].
    Bréard H; Pressat Laffouilhere T; Braund S; Duhamel O; Réal-Lhommet A; Machevin E
    Gynecol Obstet Fertil Senol; 2019 Dec; 47(12):854-859. PubMed ID: 31626980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of medications to decrease bleeding during surgical abortion: a survey of abortion providers' practices in the United States.
    Whitehouse K; Fontanilla T; Kim L; Tschann M; Soon R; Salcedo J; Kaneshiro B
    Contraception; 2018 Jun; 97(6):500-503. PubMed ID: 29490288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to manage unresponsiveness to misoprostol in failed second trimester pregnancy termination.
    Pongsatha S; Tongsong T
    J Obstet Gynaecol Res; 2013 Jan; 39(1):154-9. PubMed ID: 22691227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Misoprostol drug to be withdrawn from French market.
    Casassus B
    Lancet; 2017 Nov; 390(10110):e42. PubMed ID: 29153318
    [No Abstract]   [Full Text] [Related]  

  • 31. Manufacturer's warning regarding unapproved uses of misoprostol.
    Friedman MA
    N Engl J Med; 2001 Jan; 344(1):61. PubMed ID: 11187113
    [No Abstract]   [Full Text] [Related]  

  • 32. Off-label use of misoprostol for labor induction in Germany: a national survey.
    Voigt F; Goecke TW; Najjari L; Pecks U; Maass N; Rath W
    Eur J Obstet Gynecol Reprod Biol; 2015 Apr; 187():85-9. PubMed ID: 25553610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demographic characteristics of women with self use of misoprostol for pregnancy interruption attending Maharaj Nakorn Chiang Mai Hospital.
    Pongsatha S; Morakot N; Tongsong T
    J Med Assoc Thai; 2002 Oct; 85(10):1074-80. PubMed ID: 12501898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the introduction of a new treatment for the termination of pregnancy in The Netherlands.
    Brouns JF; Burger MP; van Wijngaarden WJ
    Acta Obstet Gynecol Scand; 2010 Sep; 89(9):1210-3. PubMed ID: 20804347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of induced labour on postpartum blood loss.
    Phillip H; Fletcher H; Reid M
    J Obstet Gynaecol; 2004 Jan; 24(1):12-5. PubMed ID: 14675973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of misoprostol for induction of labor in case of fetal death or termination of pregnancy during second or third trimester of pregnancy: Efficiency, dosage, route of administration, side effects, use in case of uterine scar].
    Clouqueur E; Coulon C; Vaast P; Chauvet A; Deruelle P; Subtil D; Houfflin-Debarge V
    J Gynecol Obstet Biol Reprod (Paris); 2014 Feb; 43(2):146-61. PubMed ID: 24461423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of misoprostol in termination of second-trimester pregnancy.
    Lin CJ; Chien SC; Chen CP
    Taiwan J Obstet Gynecol; 2011 Sep; 50(3):275-82. PubMed ID: 22030039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Misoprostol for prevention of postpartum haemorrhage in developing countries.
    Carpenter JP
    Trop Doct; 2003 Apr; 33(2):122. PubMed ID: 12680557
    [No Abstract]   [Full Text] [Related]  

  • 39. Making pregnancy safer in Myanmar: introducing misoprostol to prevent post-partum haemorrhage as part of active management of the third stage of labour.
    Htay TT
    Reprod Health Matters; 2007 Nov; 15(30):214-5. PubMed ID: 17938087
    [No Abstract]   [Full Text] [Related]  

  • 40. Misoprostol: an essential medicine for managing postpartum hemorrhage in low-resource settings?
    Rushwan H
    Int J Gynaecol Obstet; 2011 Sep; 114(3):209-10. PubMed ID: 21745664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.